Asset profile
si-544
Peptide
Evidence outlook · lead readout
NCT06191042 · Psoriasis Vulgaris, Psoriatic Arthritis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06191042: The trial randomized participants to si-544 or placebo with triple-blinding, a genuine controlled design, but its primary outcome was safety rather than disease activity, and no results have been posted yet.
Also in development:Psoriatic Arthritis · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.